189.08
Jazz Pharmaceuticals Plc stock is traded at $189.08, with a volume of 832.87K.
It is up +2.20% in the last 24 hours and down -3.94% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$185.01
Open:
$186.71
24h Volume:
832.87K
Relative Volume:
0.83
Market Cap:
$11.64B
Revenue:
$4.27B
Net Income/Loss:
$-356.15M
P/E Ratio:
-31.67
EPS:
-5.9702
Net Cash Flow:
$1.19B
1W Performance:
+4.78%
1M Performance:
-3.94%
6M Performance:
+47.95%
1Y Performance:
+39.80%
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
189.08 | 11.39B | 4.27B | -356.15M | 1.19B | -5.9702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
MassMutual Private Wealth & Trust FSB Sells 7,073 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
A Voice for Advocacy and Awareness in HER2+ Gastroesophageal AdenocarcinomaJazz Pharmaceuticals - Oncodaily
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education - Lelezard
Is Jazz Pharmaceuticals (JAZZ) one of the best cheap biotech stocks to buy now? - MSN
People with sleep disorders to get guidance on sodium, heart risk - Stock Titan
Is the options market predicting a spike in Jazz Pharmaceuticals stock? - MSN
How New Ziihera and JZP898 Data from AACR 2026 Will Impact Jazz Pharmaceuticals (JAZZ) Investors - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate - MSN
Groupama Asset Managment Lowers Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals’ EBITDA Set to Surge 175% in 2026: Here’s What’s Next - TIKR.com
Narcolepsy Therapeutics Market (2025) | Central Nervous System - openPR.com
Why is Jazz Pharmaceuticals plc stock going up2026 Technical Overview & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Piper Sandler Maintains Overweight Rating for JAZZ, Raises Price Target | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $232.00 Price Target at Piper Sandler - MarketBeat
Piper Sandler raises Jazz Pharmaceuticals stock price target on growth outlook - Investing.com UK
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026 - Yahoo Finance
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting - Yahoo Finance
Goldentree Asset Management LP Takes $149.60 Million Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals plc Denmark Finland France Germany Netherlands Sweden United Kingdom Ireland - AD HOC NEWS
JAZZ stock rises as Q4 earnings & sales top expectations - MSN
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting - Yahoo Finance
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 - PR Newswire
Faithward Advisors LLC Increases Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Swings: Can Jazz Pharmaceuticals plc ride the EV wave2026 Major Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Fundamentals Check: Can Jazz Pharmaceuticals plc ride the EV waveDip Buying & High Conviction Buy Zone Picks - baoquankhu1.vn
Holocene Advisors LP Acquires 135,367 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Ameriprise Financial Inc. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Buybacks Report: Can Jazz Pharmaceuticals plc expand its profit margins2026 PostEarnings & Growth Oriented Trade Recommendations - baoquankhu1.vn
Iron Triangle Partners LP Makes New $19.77 Million Investment in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC - MarketBeat
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Bank of Montreal Can - MarketBeat
Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential - FXEmpire
Jazz Pharmaceuticals at Barclays Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals at Barclays Conference: Strategic Growth Insights - Investing.com Nigeria
Capital World Investors Increases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary - simplywall.st
Jazz Pharmaceuticals Stock at $185: Here’s Why Analysts See a New All-Time High in 2026 - TIKR.com
Jazz’s 2025 Net Loss and 2026 Outlook Might Change The Case For Investing In JAZZ - simplywall.st
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $235,443.78 in Stock - MarketBeat
Tax-withholding share disposition by Jazz Pharmaceuticals (JAZZ) director - Stock Titan
Jazz Pharmaceuticals (JAZZ) CFO reports tax-withholding share disposition - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP has 2,503 shares withheld to cover RSU taxes - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP Patricia Carr reports share sales - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO has shares withheld to cover RSU taxes - Stock Titan
Barclays reiterates Jazz Pharmaceuticals stock rating on CNS strength - Investing.com Nigeria
Patricia Carr (NASDAQ: JAZZ) files Form 144 showing recent share sales - Stock Titan
JAZZ or ACAD: Which Is the Better Value Stock Right Now? - Yahoo Finance
S&P 500 Futures Fall in Premarket Trading; Jazz Pharmaceuticals, Live Nation Ent Lead - Barron's
American Century Companies Inc. Sells 36,599 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):